Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-05-26

Clinical Trial Update: Open-Label Lesinurad Monotherapy Extension Study in Gout [Phase 3]

View source ↗

Summary

An open-label extension study of lesinurad monotherapy for gout has completed Phase 3 research, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lesinurad (Zurampic) (lesinurad)

Snippet

Sponsor: Ardea Biosciences, Inc. | Conditions: Gout | Phase 3 | Status: COMPLETED | Results posted: 2016-05-26